Skip to main content
Premium Trial:

Request an Annual Quote

Agilix Pockets $21M in Series B Financing Round

NEW YORK, Dec. 17 - Functional genomics and proteomics technology developer Agilix has closed a Series B financing round worth $20.8 million, the firm said on Monday.

 

Burrill & Company, Hambrecht & Quist Capital Management, Stephens Group, Wheatley MedTech Partners, and BioVeda participated in the round, which also included a reinvestment by Series A investor ATP Capital.

 

The capital will help Agilix, of New Haven, Conn., commercialize and ramp up production of its FAAST whole-transcriptome analysis system and its ZeptoLabeling technology for proteomic-based drug-discovery.

 

"We appreciate the industry's enthusiasm for our technologies and we look forward to scaling our production facilities to serve our discovery partners," Martin J. Mattessich, president & CEO of Agilix, said in a statement. "This is a fundamental change in the way companies approach both gene and protein expression profiling. These technologies will allow Agilix and our partners to study new genes, pathways, and toxicology profiles in any disease system and in any model organism."

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.